This is the authors' abstract. We don't add key points for this paper.
In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. (Funded by Biogen Idec; CONFIRM ClinicalTrials.gov number, NCT00451451.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fox et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: